121124-94-5

Basic information

• Product Name: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE
• Synonyms: CHEMBRDG-BB 3005903;AURORA 10093;ART-CHEM-BB B005903;2-(BENZYLOXY)-5-BROMOBENZALDEHYDE;AKOS B005903;AKOS BBS-00006697;OTAVA-BB BB7014211657;2-(benzyloxy)-5-bromobenzaldehyde(SALTDATA: FREE)
• CAS NO: 121124-94-5
• Molecular Formula: C₁₄H₁₁BrO₂
• Molecular Weight: 291.14
• Mol File: 121124-94-5.mol
• Article Data: 52

Chemical Properties

• Melting Point: 73-74 °C
• Boiling Point: 405.3 °C at 760 mmHg
• Flash Point: 198.9 °C
• Appearance: /
• Density: 1.441 g/cm³
• Vapor Pressure: 8.86E-07mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE(121124-94-5)
• EPA Substance Registry System: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE(121124-94-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 121124-94-5(Hazardous Substances Data)

Usage

General Description

2-(Benzyloxy)-5-bromobenzaldehyde is a chemical compound with the molecular formula C14H11BrO2. It consists of a benzene ring with a bromine atom and an aldehyde group attached, as well as a benzyl ether group. 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE is commonly used in organic synthesis as a building block for creating other organic compounds. It is often used as a reagent in the preparation of various pharmaceuticals and fine chemicals. Additionally, 2-(benzyloxy)-5-bromobenzaldehyde has been studied for its potential biological activities, including its antimicrobial and antineoplastic effects.

InChI:InChI=1/C14H11BrO2/c15-13-6-7-14(12(8-13)9-16)17-10-11-4-2-1-3-5-11/h1-9H,10H2

Upstream product

• 7726-95-6 bromine 
• 127-09-3 sodium acetate 
• 64-19-7 acetic acid 
• 5896-17-3 2-(phenylmethoxy)benzaldehyde 
• 100-39-0 benzyl bromide 
• 1761-61-1 5-bromosalicyclaldehyde 
• 110-71-4 1,2-dimethoxyethane 
• 100-44-7 benzyl chloride 
• 584-08-7 potassium carbonate 

Downstream Products

• 177759-66-9 2-(5-bromo-2-benzyloxyphenyl)-1,3-dioxolane 
• 1226977-09-8 tris(2-benzyloxy-5-bromobenzyl)amine 
• 835898-37-8 1-(benzyloxy)-4-bromo-2-cyanobenzene 
• 1419748-26-7 2-benzyloxy-5-(4,4',5,5'-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile 
• 1761-61-1 5-bromosalicyclaldehyde 
• 214072-73-8 (2-(benzyloxy)-5-methoxyphenyl)methanol 
• 916441-65-1 2-[3-(tert-butyl-diphenyl-silanyloxymethyl)-4-(pyridin-3-ylmethoxy)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-59-3 3-[4-bromo-2-(tert-butyl-diphenyl-silanyloxymethyl)-phenoxymethyl]-pyridine 
• 916441-80-0 2-methyl-2-[4-(pyridin-2-ylmethoxy)-3-(2-trimethylsilanyl-ethoxymethoxymethyl)-phenyl]-propionic acid methyl ester 
• 916441-68-4 2-[4-benzyloxy-3-(2-trimethylsilanyl-ethoxymethoxymethyl)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-57-1 [2-(2-benzyloxy-5-bromo-benzyloxymethoxy)-ethyl]-trimethyl-silane 
• 916441-77-5 2-[4-hydroxy-3-(2-trimethylsilanyl-ethoxymethoxymethyl)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-83-3 2-[3-hydroxymethyl-4-(pyridin-3-ylmethoxy)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-99-1 2-[3-hydroxymethyl-4-(pyridin-2-ylmethoxy)-phenyl]-2-methyl-propionic acid methyl ester 

Relevant articles and documents

Desymmetrization of Diarylmethylamido Bis(phenols) through Peptide-Catalyzed Bromination: Enantiodivergence as a Consequence of a 2 amu Alteration at an Achiral Residue within the Catalyst

Diarylmethylamido bis(phenols) have been subjected to peptide-catalyzed, enantioselective bromination reactions. Desymmetrization of compounds in this class has been achieved such that enantioenriched products may be isolated with up to 97:3 er. Mechanist

Development of DHQ-based chemical biology probe to profile cellular targets for HBV

Chronic hepatitis B virus (HBV) infection has been a serious public health burden worldwide. Current anti-HBV therapies could not eliminate HBV ultimately. Considering the characteristics of HBV, it is impossible to be entirely cured based on current therapies. Therefore, it is urgently needed to develop novel therapeutic agents with new mechanism of action. The dihydroquinolizinone (DHQ) derivatives exhibited potent anti-HBV activity by decreasing HBV DNA and HBsAg level in an obscure mechanism of action. In this study, we have optimized the DHQ scaffold, developed the photoaffinity probe, with which to identify potential binding proteins.

Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability

We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-place preference assays in mice, and do not produce dependence. Although these attributes are promising, these analogues exhibit poor metabolic stability in mouse liver microsomes, likely due to the central tetrahydroquinoline scaffold in this series. As such, a structure-activity relationship (SAR) campaign was pursued to improve their metabolic stability. This resulted in a shift from our original bicyclic tetrahydroquinoline core to a monocyclic benzylic-core system. By eliminating one of the rings in this scaffold and exploring the SAR of this new core, two promising analogues were discovered. These analogues (5l and 5m) had potency and efficacy values at MOR better or comparable to morphine, retained their DOR-antagonist properties, and showed a 10-fold improvement in metabolic stability.